In a new study, researchers found the investigational drug finerenone reduced the risk of heart attack, stroke, heart failure in patients with chronic kidney disease, and Type 2 diabetes.
The research was conducted by a team at the National and Kapodistrian University of Athens in Greece
In the largest trial of its kind to date, the study found that finerenone reduced the risk of heart disease events for patients regardless of whether they had a history of heart disease or not.
Finerenone – a novel, nonsteroidal, selective mineralocorticoid receptor antagonist – reduced both the risk of worsening kidney disease and risk of death related to heart problems.
The researchers are pleased to see that finerenone could provide a meaningful treatment option for patients who are battling chronic conditions.
In the study, the team enrolled nearly 6,000 patients at more than 900 sites in 48 countries.
The goal was to see finerenone in patients with chronic kidney disease and Type 2 diabetes since these patients face a strong risk of cardiovascular disease and death.
Heart disease events like heart attacks, heart failure, and stroke are some of the leading causes of death in this patient group.
After a follow-up of more than 2-1/2 years, researchers found a daily, oral treatment at 10 mg or 20 mg with finerenone reduced by 14% the risk of cardiovascular events for patients who already had a history of heart disease and for those who had no previous history.
It also reduced the rate of death, heart attack, stroke, and hospitalization for heart failure among patients with chronic kidney disease and Type 2 diabetes.
There are additional phase III trials of finerenone in progress.
One author of the study is Gerasimos Filippatos, M.D.
The study was presented at the American Heart Association’s Scientific Sessions 2020 and is published in Circulation.
Copyright © 2020 Knowridge Science Report. All rights reserved.
